Pages that link to "Q39250440"

The following pages link to Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma (Q39250440):

Displaying 25 items.

• Onto better TRAILs for cancer treatment (Q26768160) (← links)
• Mesenchymal stem cells as delivery vectors for anti-tumor therapy (Q26861201) (← links)
• Engineering mesenchymal stem cells for regenerative medicine and drug delivery (Q27026414) (← links)
• Practical Issues with the Use of Stem Cells for Cancer Gene Therapy (Q28085238) (← links)
• Human umbilical cord perivascular cells exhibited enhanced migration capacity towards hepatocellular carcinoma in comparison with bone marrow mesenchymal stromal cells: a role for autocrine motility factor receptor. (Q34043094) (← links)
• Baculovirus as an ideal radionuclide reporter gene vector: a new strategy for monitoring the fate of human stem cells in vivo (Q34676290) (← links)
• E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice (Q37588372) (← links)
• Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan (Q37661559) (← links)
• Stem cell-based therapies for cancer treatment: separating hope from hype (Q38245163) (← links)
• Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. (Q38557486) (← links)
• Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects (Q38806320) (← links)
• CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies (Q38807514) (← links)
• Human Umbilical Cord Mesenchymal Stem Cells Promote Breast Cancer Metastasis by Interleukin-8- and Interleukin-6-Dependent Induction of CD44( )/CD24(-) Cells (Q38908092) (← links)
• Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. (Q38998166) (← links)
• Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition (Q39556636) (← links)
• Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells (Q40160910) (← links)
• Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure (Q40686919) (← links)
• pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo (Q42368100) (← links)
• Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy (Q50070105) (← links)
• Pro-apoptotic effect of TRAIL-transfected endothelial progenitor cells on glioma cells. (Q52653034) (← links)
• Non-coding RNAs are promising targets for stem cell-based cancer therapy. (Q64984847) (← links)
• Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy (Q90241548) (← links)
• Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation (Q91716512) (← links)
• Nanomaterial Interactions with Human Neutrophils (Q93190252) (← links)
• Mesenchymal stem/stromal cells: Developmental origin, tumorigenesis and translational cancer therapeutics (Q102061308) (← links)